Treatment-emergent adverse events occurring in ≥25% of patients for any grade or ≥5% for grade 3/4 in the MPD cohort or overall study population
| . | MPD cohort n = 52 . | Overall N = 84 . | ||
|---|---|---|---|---|
| Any grade . | Grade 3/4 . | Any grade . | Grade 3/4 . | |
| Hematologic events | ||||
| Neutropenia | 19 (36.5) | 17 (32.7) | 38 (45.2) | 32 (38.1) |
| Lymphopenia | 27 (51.9) | 25 (48.1) | 34 (40.5) | 32 (38.1) |
| Anemia | 17 (32.7) | 10 (19.2) | 32 (38.1) | 16 (19.0) |
| Thrombocytopenia | 16 (30.8) | 10 (19.2) | 29 (34.5) | 21 (25.0) |
| Leukopenia | 11 (21.2) | 6 (11.5) | 17 (20.2) | 11 (13.1) |
| Nonhematologic events | ||||
| Fatigue | 36 (69.2) | 6 (11.5) | 55 (65.5) | 6 (7.1) |
| Diarrhea | 30 (57.7) | 3 (5.8) | 47 (56.0) | 5 (6.0) |
| Cough | 21 (40.4) | 1 (1.9) | 35 (41.7) | 1 (1.2) |
| Upper respiratory tract infection | 23 (44.2) | 1 (1.9) | 34 (40.5) | 2 (2.4) |
| Pyrexia | 23 (44.2) | 0 (0) | 33 (39.3) | 0 (0) |
| Muscle spasms | 20 (38.5) | 2 (3.8) | 31 (36.9) | 2 (2.4) |
| Dyspnea | 19 (36.5) | 0 (0) | 30 (35.7) | 1 (1.2) |
| Peripheral edema | 19 (36.5) | 0 (0) | 28 (33.3) | 1 (1.2) |
| Back pain | 16 (30.8) | 1 (1.9) | 27 (32.1) | 2 (2.4) |
| Insomnia | 18 (34.6) | 0 (0) | 26 (31.0) | 0 (0) |
| Nausea | 18 (34.6) | 0 (0) | 26 (31.0) | 0 (0) |
| Hypophosphatemia | 20 (38.5) | 13 (25.0) | 25 (29.8) | 18 (21.4) |
| Hyperglycemia | 14 (26.9) | 4 (7.7) | 23 (27.4) | 11 (13.1) |
| Constipation | 14 (26.9) | 0 (0) | 22 (26.2) | 0 (0) |
| Hypokalemia | 13 (25.0) | 5 (9.6) | 22 (26.2) | 8 (9.5) |
| Arthralgia | 13 (25.0) | 1 (1.9) | 21 (25.0) | 1 (1.2) |
| Pain in extremity | 13 (25.0) | 0 (0) | 21 (25.0) | 0 (0) |
| Peripheral neuropathy* | 14 (26.9) | 1 (1.9)† | 18 (21.4) | 1 (1.2)† |
| Pneumonia | 9 (17.3) | 5 (9.6) | 13 (15.5) | 6 (7.1) |
| Hyponatremia | 8 (15.4) | 5 (9.6) | 14 (16.7) | 9 (10.7) |
| Alanine aminotransferase increased | 7 (13.5) | 4 (7.7) | 10 (11.9) | 5 (6.0) |
| Hemoglobin decreased | 4 (7.7) | 4 (7.7) | 6 (7.1) | 5 (6.0) |
| . | MPD cohort n = 52 . | Overall N = 84 . | ||
|---|---|---|---|---|
| Any grade . | Grade 3/4 . | Any grade . | Grade 3/4 . | |
| Hematologic events | ||||
| Neutropenia | 19 (36.5) | 17 (32.7) | 38 (45.2) | 32 (38.1) |
| Lymphopenia | 27 (51.9) | 25 (48.1) | 34 (40.5) | 32 (38.1) |
| Anemia | 17 (32.7) | 10 (19.2) | 32 (38.1) | 16 (19.0) |
| Thrombocytopenia | 16 (30.8) | 10 (19.2) | 29 (34.5) | 21 (25.0) |
| Leukopenia | 11 (21.2) | 6 (11.5) | 17 (20.2) | 11 (13.1) |
| Nonhematologic events | ||||
| Fatigue | 36 (69.2) | 6 (11.5) | 55 (65.5) | 6 (7.1) |
| Diarrhea | 30 (57.7) | 3 (5.8) | 47 (56.0) | 5 (6.0) |
| Cough | 21 (40.4) | 1 (1.9) | 35 (41.7) | 1 (1.2) |
| Upper respiratory tract infection | 23 (44.2) | 1 (1.9) | 34 (40.5) | 2 (2.4) |
| Pyrexia | 23 (44.2) | 0 (0) | 33 (39.3) | 0 (0) |
| Muscle spasms | 20 (38.5) | 2 (3.8) | 31 (36.9) | 2 (2.4) |
| Dyspnea | 19 (36.5) | 0 (0) | 30 (35.7) | 1 (1.2) |
| Peripheral edema | 19 (36.5) | 0 (0) | 28 (33.3) | 1 (1.2) |
| Back pain | 16 (30.8) | 1 (1.9) | 27 (32.1) | 2 (2.4) |
| Insomnia | 18 (34.6) | 0 (0) | 26 (31.0) | 0 (0) |
| Nausea | 18 (34.6) | 0 (0) | 26 (31.0) | 0 (0) |
| Hypophosphatemia | 20 (38.5) | 13 (25.0) | 25 (29.8) | 18 (21.4) |
| Hyperglycemia | 14 (26.9) | 4 (7.7) | 23 (27.4) | 11 (13.1) |
| Constipation | 14 (26.9) | 0 (0) | 22 (26.2) | 0 (0) |
| Hypokalemia | 13 (25.0) | 5 (9.6) | 22 (26.2) | 8 (9.5) |
| Arthralgia | 13 (25.0) | 1 (1.9) | 21 (25.0) | 1 (1.2) |
| Pain in extremity | 13 (25.0) | 0 (0) | 21 (25.0) | 0 (0) |
| Peripheral neuropathy* | 14 (26.9) | 1 (1.9)† | 18 (21.4) | 1 (1.2)† |
| Pneumonia | 9 (17.3) | 5 (9.6) | 13 (15.5) | 6 (7.1) |
| Hyponatremia | 8 (15.4) | 5 (9.6) | 14 (16.7) | 9 (10.7) |
| Alanine aminotransferase increased | 7 (13.5) | 4 (7.7) | 10 (11.9) | 5 (6.0) |
| Hemoglobin decreased | 4 (7.7) | 4 (7.7) | 6 (7.1) | 5 (6.0) |